TeVido BioDevices Announces Appointment of Dr. John Harris to Advisory Board

My Subscriptions

Payment Confirmation

Transaction Failed

Your transaction failed, please try again or contact site support.

TeVido BioDevices (cellular therapy to treat loss of pigmentation) today announced the appointment to the advisory board of Dr. John Harris, Director of the Vitiligo Clinic and Research Center at the University of Massachusetts Medical School. Dr. Harris will leverage his extensive experience in the research, diagnosis and treatment of vitiligo to help address significant unmet needs in reconstructive and cosmetic procedures utilizing autologous cell therapy (using a patient’s own tissue) for patients with vitiligo as well as nipple areola reconstruction for breast cancer survivors.

Laura Bosworth, TeVido CEO:  “TeVido’s mission has always been about helping patients to feel “whole” again.”  Bosworth added, “As we developed our cell therapy techniques to re-pigment the nipple areola lost due to breast cancer, we realized the procedure could benefit patients with vitiligo. Bringing Dr. Harris on our advisory board will accelerate our development plan to make a meaningful difference in the lives of those suffering from vitiligo, while we expand treatment options to include areola re-pigmentation and scarring.”

Vitiligo is a skin condition characterized by the appearance of white patches on any part of the body, such as the face, hands and arms. There is no cure, and it can be psychologically devastating.

“I am excited to contribute to the meaningful work TeVido is doing in the area of vitiligo treatment,” said Dr. Harris. “Vitiligo can cause severe emotional distress and social stigma. The ground-breaking techniques TeVido will bring to market will have a profound impact on the quality of patients’ lives.”

Dr. John Harris, Advisor, is a key opinion leader in vitiligo and has multiple research publications and textbook chapters on vitiligo. He serves on the Dermatology Foundation, Skin of Color Society, Global Vitiligo Foundation, Vitiligo Research Foundation, and the American Academy of Dermatology. He is an advisor and collaborator with AbbVie, Combe Inc, Genzyme/Sanofi, Stiefel/GSK, Aclaris Therapeutics, Celgene, and Pfizer. He is an ad hoc reviewer on grant applications and for multiple research journals. He lectures on vitiligo and other topics to local, regional, national, and international audiences.

Dr. Harris will be speaking on a panel with other vitiligo experts at World Vitiligo Day. The annual international event that brings global awareness to this life-altering skin condition, will be held in Detroit, Michigan on June 25th.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.